Combination of farnesyltransferase and Akt inhibitors is synergistic in breast cancer cells and causes significant breast tumor regression in ErbB2 transgenic mice

Maria E. Balasis, Kara D. Forinash, Y. Ann Chen, William J. Fulp, Domenico Coppola, Andrew Hamilton, Jin Q. Cheng, Saïd M. Sebti

Research output: Contribution to journalArticle

Abstract

The Akt activation inhibitor triciribine and the farnesyltransferase inhibitor tipifarnib have modest to little activity in clinical trials when used as single agents. In this article, preclinical data show that the combination is more effective than single agents both in cultured cells and in vivo. Combination index data analysis shows that this combination is highly synergistic at inhibiting anchorage-dependent growth of breast cancer cells. This synergistic interaction is also observed with structurally unrelated inhibitors of Akt (MK-2206) and farnesyltransferase (FTI-2153). The triciribine/tipifarnib synergistic effects are seen with several cancer cell lines including those from breast, leukemia, multiple myeloma and lung tumors with different genetic alterations such as K-Ras, B-Raf, PI3K (phosphoinositide 3-kinase), p53 and pRb mutations, PTEN, pRB and Ink4a deletions, and ErbB receptor overexpression. Furthermore, the combination is synergistic at inhibiting anchorage-independent growth and at inducing apoptosis in breast cancer cells. The combination is also more effective at inhibiting the Akt/mTOR/S6 kinase pathway. In an ErbB2-driven breast tumor transgenic mouse model, the combination, but not single agent, treatment with triciribine and tipifarnib induces significant breast tumor regression. Our findings warrant further investigation of the combination of farnesyltransferase and Akt inhibitors.

Original languageEnglish (US)
Pages (from-to)2852-2862
Number of pages11
JournalClinical Cancer Research
Volume17
Issue number9
DOIs
StatePublished - May 1 2011

Fingerprint

triciribine
Farnesyltranstransferase
tipifarnib
Transgenic Mice
Breast Neoplasms
Ribosomal Protein S6 Kinases
1-Phosphatidylinositol 4-Kinase
Growth
Multiple Myeloma
Cultured Cells
Neoplasms
Leukemia
Breast
Clinical Trials
Apoptosis
Cell Line
Lung
Mutation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Combination of farnesyltransferase and Akt inhibitors is synergistic in breast cancer cells and causes significant breast tumor regression in ErbB2 transgenic mice. / Balasis, Maria E.; Forinash, Kara D.; Chen, Y. Ann; Fulp, William J.; Coppola, Domenico; Hamilton, Andrew; Cheng, Jin Q.; Sebti, Saïd M.

In: Clinical Cancer Research, Vol. 17, No. 9, 01.05.2011, p. 2852-2862.

Research output: Contribution to journalArticle

Balasis, Maria E. ; Forinash, Kara D. ; Chen, Y. Ann ; Fulp, William J. ; Coppola, Domenico ; Hamilton, Andrew ; Cheng, Jin Q. ; Sebti, Saïd M. / Combination of farnesyltransferase and Akt inhibitors is synergistic in breast cancer cells and causes significant breast tumor regression in ErbB2 transgenic mice. In: Clinical Cancer Research. 2011 ; Vol. 17, No. 9. pp. 2852-2862.
@article{713aa0b9a3cc4be1ba4cb5a744bf2d29,
title = "Combination of farnesyltransferase and Akt inhibitors is synergistic in breast cancer cells and causes significant breast tumor regression in ErbB2 transgenic mice",
abstract = "The Akt activation inhibitor triciribine and the farnesyltransferase inhibitor tipifarnib have modest to little activity in clinical trials when used as single agents. In this article, preclinical data show that the combination is more effective than single agents both in cultured cells and in vivo. Combination index data analysis shows that this combination is highly synergistic at inhibiting anchorage-dependent growth of breast cancer cells. This synergistic interaction is also observed with structurally unrelated inhibitors of Akt (MK-2206) and farnesyltransferase (FTI-2153). The triciribine/tipifarnib synergistic effects are seen with several cancer cell lines including those from breast, leukemia, multiple myeloma and lung tumors with different genetic alterations such as K-Ras, B-Raf, PI3K (phosphoinositide 3-kinase), p53 and pRb mutations, PTEN, pRB and Ink4a deletions, and ErbB receptor overexpression. Furthermore, the combination is synergistic at inhibiting anchorage-independent growth and at inducing apoptosis in breast cancer cells. The combination is also more effective at inhibiting the Akt/mTOR/S6 kinase pathway. In an ErbB2-driven breast tumor transgenic mouse model, the combination, but not single agent, treatment with triciribine and tipifarnib induces significant breast tumor regression. Our findings warrant further investigation of the combination of farnesyltransferase and Akt inhibitors.",
author = "Balasis, {Maria E.} and Forinash, {Kara D.} and Chen, {Y. Ann} and Fulp, {William J.} and Domenico Coppola and Andrew Hamilton and Cheng, {Jin Q.} and Sebti, {Sa{\"i}d M.}",
year = "2011",
month = "5",
day = "1",
doi = "10.1158/1078-0432.CCR-10-2544",
language = "English (US)",
volume = "17",
pages = "2852--2862",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Combination of farnesyltransferase and Akt inhibitors is synergistic in breast cancer cells and causes significant breast tumor regression in ErbB2 transgenic mice

AU - Balasis, Maria E.

AU - Forinash, Kara D.

AU - Chen, Y. Ann

AU - Fulp, William J.

AU - Coppola, Domenico

AU - Hamilton, Andrew

AU - Cheng, Jin Q.

AU - Sebti, Saïd M.

PY - 2011/5/1

Y1 - 2011/5/1

N2 - The Akt activation inhibitor triciribine and the farnesyltransferase inhibitor tipifarnib have modest to little activity in clinical trials when used as single agents. In this article, preclinical data show that the combination is more effective than single agents both in cultured cells and in vivo. Combination index data analysis shows that this combination is highly synergistic at inhibiting anchorage-dependent growth of breast cancer cells. This synergistic interaction is also observed with structurally unrelated inhibitors of Akt (MK-2206) and farnesyltransferase (FTI-2153). The triciribine/tipifarnib synergistic effects are seen with several cancer cell lines including those from breast, leukemia, multiple myeloma and lung tumors with different genetic alterations such as K-Ras, B-Raf, PI3K (phosphoinositide 3-kinase), p53 and pRb mutations, PTEN, pRB and Ink4a deletions, and ErbB receptor overexpression. Furthermore, the combination is synergistic at inhibiting anchorage-independent growth and at inducing apoptosis in breast cancer cells. The combination is also more effective at inhibiting the Akt/mTOR/S6 kinase pathway. In an ErbB2-driven breast tumor transgenic mouse model, the combination, but not single agent, treatment with triciribine and tipifarnib induces significant breast tumor regression. Our findings warrant further investigation of the combination of farnesyltransferase and Akt inhibitors.

AB - The Akt activation inhibitor triciribine and the farnesyltransferase inhibitor tipifarnib have modest to little activity in clinical trials when used as single agents. In this article, preclinical data show that the combination is more effective than single agents both in cultured cells and in vivo. Combination index data analysis shows that this combination is highly synergistic at inhibiting anchorage-dependent growth of breast cancer cells. This synergistic interaction is also observed with structurally unrelated inhibitors of Akt (MK-2206) and farnesyltransferase (FTI-2153). The triciribine/tipifarnib synergistic effects are seen with several cancer cell lines including those from breast, leukemia, multiple myeloma and lung tumors with different genetic alterations such as K-Ras, B-Raf, PI3K (phosphoinositide 3-kinase), p53 and pRb mutations, PTEN, pRB and Ink4a deletions, and ErbB receptor overexpression. Furthermore, the combination is synergistic at inhibiting anchorage-independent growth and at inducing apoptosis in breast cancer cells. The combination is also more effective at inhibiting the Akt/mTOR/S6 kinase pathway. In an ErbB2-driven breast tumor transgenic mouse model, the combination, but not single agent, treatment with triciribine and tipifarnib induces significant breast tumor regression. Our findings warrant further investigation of the combination of farnesyltransferase and Akt inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=79955504184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955504184&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-10-2544

DO - 10.1158/1078-0432.CCR-10-2544

M3 - Article

C2 - 21536547

AN - SCOPUS:79955504184

VL - 17

SP - 2852

EP - 2862

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 9

ER -